top of page
 THE PACE

New therapies / indications available since the last 12 months 

VAXIGRIP®

BY:

Dr. Feng Xue

Dec 19, 2025

  • 微信图片_20260414172211_190_280
  • 微信图片_20260414172239_191_280

VAXIGRIP®(influenza virus)SANOFIHK Reg. No. HK-68857 (24 Sep, 2025)

Composition:2

• VAXIGRIP® is a trivalent influenza vaccine available as a 0.5 ml suspension for injection in a pre-filled syringe. It contains inactivated, split influenza virus strains (H1N1, H3N2-like, and b/brisbane/60/2008-like)

 

Indication:2

VAXIGRIP® is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the influenza B virus type contained in the vaccine for:

• active immunization of adults, including pregnant women, and children from 6 months of age and older

• passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women

The use of VAXIGRIP® should be based on official recommendations on vaccination against influenza

 

References2. EMC. Vaxigrip suspension for injection in pre-filled syringe. 9 July 2025. Available from: https://www.medicines.org.uk/emc/product/100673/smpc#gref. [Accessed 18 November 2025].

 

POPULAR STORY

Uncovering the Tricks of the Silent Thief of Sight

Dr. Roy Lau

Dec 19, 2024

What’s New in Coronary Artery Disease?

Dr. Roy Lau

Aug 20, 2024

Challenges and Strategies for Managing CHB Patients with Co-morbidities

Dr. Roy Lau

Jun 21, 2024

Decoding the Paradox on Impact of Obesity on Cognitive Functioning

Dr. Roy Lau

Jun 20, 2024

Gain Without Pain – Revisiting the Pain Management in Rheumatoid Arthritis

Dr. Roy Lau

Oct 22, 2024

Uncovering the Art of Perfect Matching – A Review on Precision Oncology

Dr. Roy Lau

Feb 17, 2025

bottom of page